Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kezar Life Sciences (KZR) Cash from Financing Activities (2021 - 2025)

Kezar Life Sciences (KZR) has disclosed Cash from Financing Activities for 5 consecutive years, with -$6.7 million as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities fell 14370.21% to -$6.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$10.6 million through Dec 2025, down 10376.7% year-over-year, with the annual reading at -$10.6 million for FY2025, 10376.7% down from the prior year.
  • Cash from Financing Activities hit -$6.7 million in Q4 2025 for Kezar Life Sciences, down from -$1.3 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $99.4 million in Q4 2021 to a low of -$6.7 million in Q4 2025.
  • Historically, Cash from Financing Activities has averaged $12.8 million across 5 years, with a median of $169500.0 in 2022.
  • Biggest five-year swings in Cash from Financing Activities: surged 27673.76% in 2022 and later crashed 14370.21% in 2025.
  • Year by year, Cash from Financing Activities stood at $99.4 million in 2021, then plummeted by 99.49% to $506000.0 in 2022, then tumbled by 88.34% to $59000.0 in 2023, then dropped by 20.34% to $47000.0 in 2024, then plummeted by 14370.21% to -$6.7 million in 2025.
  • Business Quant data shows Cash from Financing Activities for KZR at -$6.7 million in Q4 2025, -$1.3 million in Q3 2025, and -$1.3 million in Q2 2025.